Wells Fargo
ANAB icon

Wells Fargo’s AnaptysBio ANAB Stock Holding History

Wells Fargo’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-50,000
Closed -$192K – 6159
2019
Q4 		$192K Buy
+50,000
New +$1.18M ﹤0.01% 4970

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Wells Fargo's ANAB Position: Q2 2026 in Review

Wells Fargo increased its AnaptysBio (ANAB) stake by 26% in Q2 2026, buying an estimated $517K and bringing the position to 41,707 shares worth $2.82M. The position accounts for ﹤0.01% of the portfolio, ranked #3327.

Wells Fargo first reported a position in ANAB in Q1 2017 and has held it in 37 quarters since. The position peaked at $29.9M in Q3 2018. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Wells Fargo held 41,707 shares of AnaptysBio worth $2.82M as of Q2 2026.
  • Wells Fargo bought 8,527 AnaptysBio shares in Q2 2026, an estimated $517K.
  • AnaptysBio made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3327 holding.
  • Wells Fargo first reported a position in AnaptysBio in Q1 2017 and has held it in 37 quarters since.
  • Wells Fargo's AnaptysBio position peaked at $29.9M in Q3 2018.
  • 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.